Overview

A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, controlled, randomized phase 2 study designed to evaluate the safety and efficacy profile of GNS561 in patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Genoscience Pharma